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ABSTRACI‘

The invention relates to a novel method of administer

ing propranolol, a known B-andrenergic blocking agent
widely used in the treatment of angina pectoris, ar

rhythmias, hypertension and other cardiac conditions,
and migraine. The invention further relates to novel
dosage forms of propranolol which are adapted for
nasal administration and which include solutions, sus

pensions, gels and ointments.
7 Claims, 3 Drawing Figures

Stern, Arzmit. Forsch, vol. 24, 1974, pp. 70-71.
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NASAL ADMINISTRATION OF PROPRANOLOL

BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates to a novel method of

administering propranolol, a B-andrenergic-blocking

2
DETAILED DESCRIPTION OF THE
INVENTION

The word “propranolol” as used herein is intended to

encompass any pharmaceutically acceptable form of
propranolol, i.e., the free base or a pharmaceutically
acceptable salt or ester thereof. Propranolol, or l-(iso
propylamino)-3-(l-naphthyloxy)-2-propanol, can be

agent, and to novel dosage forms containing proprano
represented by the structural formula:
lol adapted for nasal administration.
10
2. Description of the Prior Art
on
Propranolol, a B-andrenergic-blocking agent, is
ocmcncnmncmcm);
widely used therapeutically, chiefly in the management
of hypertension and in the treatment of angina pectoris,
arrhythmias and other cardiac conditions, and migraine.

The drug is, however, inef?ciently- and variably ab
sorbed from oral dosage forms. Thus, Shand et al, Clin.
Pharmacol. Therap. 11, 112-120 (1970), report that a
study in humans has shown that following oral adminis
tration of propranolol, peak plasma levels in ?ve sub
jects given 80 mg oral doses varied seven fold, while
levels for 10 mg intravenous doses in the same subjects

varied only two fold. Furthermore, the bioavailability
of propranolol in some subjects as calculated from the
ratio of the area under the curve of an 80 mg oral dose
and 10 mg I.V. dose was found to be as low as 16%. The
variations in the blood levels as well as the low bioavail

ability for oral doses has been attributed by various
researchers to the extensive metabolism of the drug in

the gastrointestinal tract during the absorption process
and/or to the effect of the ?rst pass through the liver

[Dollery et al, Ann, NY. Acad. Sci. 179, 109 (1971);
Suzuki et al, Chem, Pharm. Bull. 20, 2731 (1972); and
Garceau et al, J. Pharm. Sci. 67, 1360 (1978)].
SUMMARY OF THE INVENTION

Details of the chemical synthesis of the free base, as well
as a description of pharmaceutically acceptable esters
and salts which can be derived thereform, are set forth

in Crowther et
incorporated by
According to
prisingly found

al US. Pat. No. 3,337,628, expressly
reference herein and relied upon.
the present invention, it has been sur
that propranolol can be administered
nasally with results considerably superior to those ob
tained with oral administration. The following study
was undertaken to examine the bioavailability of pro

pranolol from nasal solution in comparison with the
bioavailability of the drug when administered orally
and intravenously.
Sprague Dawley male rats, each weighing about 270
grams, were used in this study. For nasal administration,
the rats were anesthetized using sodium pentobarbital
35 (50 mg/kg) and the drug was administered to the nasal
cavity by means of a micropipet at dosage levels of 1
mg/rat and 2 mg/rat in 0.1 ml of isotonic buffer solution

In view of the foregoing, it is apparent that a serious

(pH 7.2) according to the procedure described by Hirai

need exists for the improved delivery of propranolol.
Thus, it is an object of the present invention to provide

et al, the 98th Annual Meeting of Pharmaceutical Soci

ety of Japan, Okayama, April 1978. For intravenous

novel dosage forms and a novel method of administer

administration, the rats were anesthetized and a 1 mg

ing propranolol which will provide enhanced bioavaila

dose of the drug in 0.2 ml isotonic buffer solution (pH
7.2) was injected into each rat through the femoral vein.
After intravenous and nasal administration, blood from
viding relative ease of administration when compared 45 the femoral aorta was sampled periodically. For oral

bility and minimized variations in blood levels as com
pared to oral dosage forms, while at the same time pro
to the intravenous route.

The foregoing object, resulting in bioavailability of
propranolol comparable to that achieved by intrave
nous administration but without the disadvantages in
herent-in that route of administration, is achieved by
nasal administration of propranolol. According to the

invention, the propranolol is conveniently administered
via a novel nasal dosage form, i.e., a solution, suspen

sion, ointment or gel adapted for nasal administration.
BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a semi-logarithmic plot of average blood
levels of propranolol in rats obtained when the drug
was administered via nasal, oral and intravenous routes;
FIG. 2 is a semi-logarithmic plot of mean plasma

levels of propranolol in dogs after administration of 20
mg doses via nasal, intravenous and oral administration;

administration, the rats were not anesthetized and l

mg/rat doses of the drug in 1 ml isotonic buffer solution
(pH 7.2) were administered by means of a stomach tube.
After oral administration, blood from the tail vein was

sampled periodically. Blood levels of the drug were
determined spectrophoto?uorometrically by a minor
modi?cation of the method‘ of Suzuki et a1, Chem.
Pharm. Bull. 20, 2731 (1972).
FIG. 1 shows the mean blood levels of propranolol
for the study described above. As seen from FIG. 1, the
blood level of the drug after nasal administration of a 1
mg dose is identical to the blood level after intravenous
administration of a 1 mg dose, whereas oral administra
tion at the same dosage level results in considerably
lower blood levels. The oral bioavailabilities calculated
from the ratio of the area under the curve
oral

oral

X 100 and
X 100
and
l.V.
nasal
FIG 3 is a semi-logarithmic plot of mean blood levels 65
of propranolol in rats after nasal administration of 1 mg
within 4 hours after administration were found to be
doses via a nasal solution and via a sustained release
about 15%. Table I below shows the area under the
nasal gel.
curve (AUC) within 4 hours after intravenous, nasal
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and oral administration of propranolol (l mg/rat) in
rats.

.

TABLE I
AREA UNDER CURVE (AUC) WITHIN 4 HOURS AFrER
INTRAVENOUS, NASAL AND ORAL ADMINISTRATION

OF PROPRANOLOL (1 mg) IN RATS

AUC‘
Route

(ng hr0m1"1)

Ratio

Intravenous

807.2 i 32.9‘

—

Nasal
Oral

804.0 i 56.4
144.5 i 22.8

0.996
0.179

4

sorbed from the nasal mucosa into systemic blood with
out the ?rst pass metabolism.
Propranolol can be conveniently administered na

sally to warm-blooded animals by formulating it into a
5

nasal dosage form comprising propranolol and a non

toxic pharmaceutically acceptable nasal carrier there

Percentage

for. As indicated earlier, propranolol can be employed

Absorbed Compared

in the form of the free base or in the form of a pharma

to LV. Route

ceutically acceptable salt or ester thereof, e.g., propran
10 olol hydrochloride or propranolol stearate. Suitable

99.6%
17.9%

nontoxic pharmaceutically acceptable nasal carriers

‘mean t SE

It can also be seen from FIG. 1 that the area under the

blood level curve is directly proportional to the dose,
when the drug is administered nasally. Further, it can be
seen that propranolol is very rapidly absorbed from the
nasal mucosa; thus, the peak plasma level is attained
within 5 minutes of the instillation of the nose drops.
The advantages of nasal administration as compared
to oral administration has also been demonstrated in
tests in dogs. Details of the test procedure areset forth
below.
Three beagle dogs weighing about 10 kg each were
used for this crossover study. For nasal administration,
the dogs were anesthetized with the intravenous injec
tion of 30 mg/kg of sodium pentobarbital, and 0.2 ml of

saline solution containing propranolol hydrochloride
(2O mg/dog) was then administered to the nasal cavity
via a micropipet. For intravenous administration, the
dogs were anesthetized and a 20 mg/dog dose of the

drug in 1.0 ml saline solution was injected through the
foreleg vein. For oral administration, the dogs were not
anesthetized and a 20 mg/dog dose of the drug in 50 ml
of water was administered via a stomach tube. After

nasal, intravenous and oral administration, blood was
sampled from the foreleg vein periodically. Plasma
levels of propranolol were determined spectrophoto

?uorometrically by a minor modi?cation of the method
of Shand et a1, Clin. Pharmacol. Therap. 11, 112-120

(1970).

will be apparent to those skilled in the art of nasal phar
maceutical formulations. For those not skilled in the art,
reference is made to the text entitled “REMINGTON’S

PHARMACEUTICAL SCIENCES”, 14th edition,
1970. Obviously, the choice of suitable carriers will
depend on the exact nature of the particular nasal dos
age form desired, e.g., whether propranolol is to be
formulated into a nasal solution (for use as drops or as a
spray), a nasal suspension, a nasal ointment or a nasal

gel. Preferred nasal dosage forms are solutions and gels,
which contain a major amount of water (preferably
puri?ed water) in addition to the active 'ingredient.
Minor amounts of other ingredients such as pH adjust
ers (e.g., a base such as NaOH), buffering agents, preser

vatives, wetting agents and jelling agents (e.g., methyl
cellulose) may also be present.
Examples of the preparation of a typical nasal solu
tion and of a sustained release nasal gel containing pro
pranolol are set forth below. However, it is to be under

stood that these examples are given by way of illustra
tion only and are not to be construed as limiting the
invention either in spirit or in scope as many modi?ca
tions both in materials and in methods will be apparent
to those skilled in the art.

EXAMPLE 1
2 Grams of propranolol hydrochloride were dis

solved in 80 m1 of distilled water and the pH of the
resultant solution was adjusted to 7.4 with dilute sodium
hydroxide solution. A quantity of water suf?cient to
bring the total volume to 100 ml was then added. The
solution was sterilized by being passed through a 0.2

FIG. 2 shows the mean plasma levels of propranolol
for the study described immediately above. As can be
micron Millipore ?lter.
seen from FIG. 2, the plasma levels of the drug after 45
intravenous and nasal administration are virtually iden
EXAMPLE 2
tical, whereas oral administration results in considera
80 Grams of water were heated to 80° C. and 3.0
bly lower plasma levels. Table II below summarizes the
grams of Methocel were added, with stirring. The resul
results obtained for each individual dog for the three
tant mixture was allowed to stand at room temperature
routes of administration.

for 3 hours. Then, 1.84 grams of propranolol stearate
TABLE II

I AREA UNDER PLASMA CURVE WITHIN 8 HOURS AFTER

INTRAVENOUS, NASAL AND ORAL ADMINISTRATION OF

Intravenous

Dog
N106
J096
1196
Mean
SE

PROPRANOLOL (20 mg) IN DOGS
Nasal
Oral
AUC {Nasal}

(ng hr ml_l) (ng hr ml_l) (ng hr ml_')
1702.6
1548.1
1534.9
1595.2
53.8

1648.0
1538.9
1556.3
1581.0
33.7

151.8
93.8
117.9
120.8
17.0

AUC (PDQ

AUC (I.V.)

AUC (I.V.)

0.967
0.994
1.013
0.991
0.013

0.089
0.059
0.076
0.074
0.008

As can be seen from Table II supra, the bioavailabil
were suspended in 20 grams of water and the suspension
ity of propranolol from the oral route is only 7.4% of
was added to the gel and thoroughly mixed.
that of the intravenous route, whereas the bioavailabil 65
A sustained release gel prepared as described above
ity from the nasal route is 99.1% that of the intravenous
was nasally administered to rats at the l mg/rat dosage

route. These results and those from the study in rats

detailed above indicate that propranolol is rapidly ab

level. FIG. 3 shows the mean blood levels of proprano
lol obtained as compared to those obtained for a 1 mg
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dose of nasal solution. The plot clearly shows that pro
longed release of propranolol can be achieved via nasal

6

the scope of the present invention be limited solely by
the scope of the following claims.

administration.

What is claimed is:

1. A method for eliciting a B-andrenergic blocking

EXAMPLE 3

response in a warm-blooded animal in need of such

A novel dosage form of an aqueous solution of pro
pranolol in a pharmaceutical vehicle and suitable for use
as nasal drops or nasal spray was prepared. The ?nal

mal a therapeutically effective amount of a compound

therapy, comprising nasally administering to said ani
having the formula:

composition, adjusted to pH 7.4, had the following

composition:
INGREDIENT

AMOUNT

propranolol hydrochloride

500 mg

Tween 80

2 mg

methyl cellulose

20 mg

water

10 ml.

15

or nontoxic pharmaceutically acceptable derivative

Naturally, the therapeutic dosage range for nasal
administration of propranolol acording to the present

thereof.
2. The method as de?ned by claim 1, said compound

invention will vary with the size of the patient and the
condition for which the drug is administered. A typical
dose of propranolol would be 10 to 100 mg adminis

being nasally administered together with a nontoxic
pharmaceutically acceptable nasal carrier therefor.

tered nasally three times daily. The quantity of nasal

being af?icted with angina pectoris.

3. The method as de?ned by claims 1 or 2, said animal

dosage form needed to deliver the desired dose will of 25
4. The method as de?ned by claims 1 or 2, said animal
course depend on the concentration of propranolol in
being afflicted with arrhythmias.
the composition. The volume of solution or gel which
5. The method as de?ned by claims 1 or 2, said animal
would be needed to deliver the typical dose of active
being af?icted with hypertension.
ingredient speci?ed above would be 0.1 0.5 ml of 10%
6. The method as de?ned by claims 1 or 2, said animal
solution or gel.
“
30 being afflicted with migraine.
While the invention has been described in terms of
7. The method as de?ned by claim 2, said compound
various preferred embodiments, the skilled artisan will
being administered from a form selected from the group

appreciate that various modi?cations, substitutions,

consisting of nasal solution, nasal suspension, nasal oint
ment, nasal gel, and nasal sustained release gel.

omissions and additions may be made without departing

from the spirit thereof. Accordingly, it is intended that 35
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